{"id":"kx-826-5-bid","safety":{"commonSideEffects":[{"rate":null,"effect":"Scalp irritation"},{"rate":null,"effect":"Erythema"},{"rate":null,"effect":"Pruritus"}]},"_chembl":{"chemblId":"CHEMBL3907057","moleculeType":"Small molecule","molecularWeight":"558.54"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"KX-826 works by blocking the androgen receptor in dermal papilla cells and other hair follicle structures, preventing dihydrotestosterone (DHT) from triggering hair loss. By locally antagonizing androgen signaling without systemic absorption, it aims to halt hair miniaturization and promote hair growth while minimizing systemic side effects associated with oral antiandrogens.","oneSentence":"KX-826 is a topical androgen receptor antagonist that inhibits DHT-mediated signaling in hair follicles to treat androgenetic alopecia.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:17:58.453Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Androgenetic alopecia (male pattern baldness)"}]},"trialDetails":[{"nctId":"NCT06409650","phase":"PHASE2","title":"To Evaluate Safety and Efficacy of KX-826 in Chinese Female Subjects With Androgenetic Alopecia","status":"COMPLETED","sponsor":"Suzhou Koshine Biomedica, Inc.","startDate":"2021-11-09","conditions":"Alopecia","enrollment":160},{"nctId":"NCT06126965","phase":"PHASE3","title":"Phase III Study of KX-826 With Adult Male Patients With AGA","status":"UNKNOWN","sponsor":"Suzhou Kintor Pharmaceutical Inc,","startDate":"2021-12-29","conditions":"Androgenetic Alopecia","enrollment":740},{"nctId":"NCT05940506","phase":"PHASE2","title":"Phase II Study Evaluating the Efficacy and Safety of KX-826","status":"COMPLETED","sponsor":"Suzhou Kintor Pharmaceutical Inc,","startDate":"2020-09-28","conditions":"Androgenetic Alopecia (AGA)","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["KX-826-5 mg(5%)60mL BID"],"phase":"phase_3","status":"active","brandName":"KX-826-（5%） BID","genericName":"KX-826-（5%） BID","companyName":"Suzhou Kintor Pharmaceutical Inc,","companyId":"suzhou-kintor-pharmaceutical-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"KX-826 is a topical androgen receptor antagonist that inhibits DHT-mediated signaling in hair follicles to treat androgenetic alopecia. Used for Androgenetic alopecia (male pattern baldness).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}